E. Canestrari

发表

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.

V. Catalano, I. Floriani, G. Schiavon, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy.

G. Watanabe, V. Catalano, K. Kawakami, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlative Analysis of miRNA Expression and Oncotype Dx Recurrence Score in Estrogen Receptor Positive Breast Carcinomas

J. Frasor, Yang Dai, E. Wiley, 2015, PloS one.

High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease.

V. Catalano, D. Rossi, G. Fiorentini, 2012, The oncologist.

High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice.

M. Caraglia, G. Colucci, B. Vincenzi, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

V. Catalano, B. Vincenzi, G. Tonini, 2011, BMC Cancer.

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy

V. Catalano, G. Schiavon, D. Santini, 2008, The Pharmacogenomics Journal.

Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients.

B. Vincenzi, D. Santini, G. Tonini, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.

I. Floriani, A. Russo, B. Vincenzi, 2008, The oncologist.

Human Platelet Lysate Media Supplement Supports Lentiviral Transduction and Expansion of Human T Lymphocytes While Maintaining Memory Phenotype

E. Canestrari, C. T. Dann, S. Charlebois, 2019, Journal of immunology research.

Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy

V. Catalano, B. Vincenzi, D. Santini, 2008, British Journal of Cancer.

C-MET gene copy number variation (CNV) analysis by quantitative PCR (qPCR) assay in Caucasian patients with gastric cancer (GC).

F. Cappuzzo, V. Catalano, M. Magnani, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High resolution melting (HRM) analysis for the detection of ER22/23EK, BclI, and N363S polymorphisms of the glucocorticoid receptor gene

A. Latiano, V. Annese, M. Magnani, 2009, The Journal of Steroid Biochemistry and Molecular Biology.

6115 VEGF gene polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)

D. Santini, K. Bencardino, F. Graziano, 2009 .

Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer

V. Catalano, M. Magnani, F. Graziano, 2007, Clinical chemistry and laboratory medicine.

Autologous Muscle‐Derived Cell Therapy for Swallowing Impairment in Patients Following Treatment for Head and Neck Cancer

P. Belafsky, N. Nativ-Zeltzer, J. Nolta, 2021, The Laryngoscope.

Rescuing dicer defects via inhibition of an anti-dicing nuclease.

Jeffrey K. Mito, Z. Paroo, J. Baraban, 2014, Cell reports.

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

G. Fontanini, V. Catalano, I. Floriani, 2009, British Journal of Cancer.

Ribonucleases as Drug Targets.

Z. Paroo, E. Canestrari, 2018, Trends in pharmacological sciences.

A druggable target for rescuing microRNA defects.

Z. Paroo, E. Canestrari, Ken Asada, 2016, Bioorganic & medicinal chemistry letters.

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

N. Funel, I. Floriani, G. Schiavon, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.

E. Vasile, B. Vincenzi, G. Tonini, 2011, Critical reviews in oncology/hematology.

Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.

V. Catalano, I. Floriani, G. Schiavon, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population

G. Tonini, M. Magnani, F. Graziano, 2009, International Journal of Colorectal Disease.

Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab–irinotecan

V. Catalano, B. Vincenzi, D. Santini, 2010, The Pharmacogenomics Journal.

Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype.

V. Catalano, D. Santini, S. Panunzi, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity

C. Ramos, E. Canestrari, A. Leen, 2019, Journal of Immunotherapy for Cancer.

Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy.

V. Catalano, B. Vincenzi, G. Tonini, 2010, Pharmacogenomics.

PHLDA1 Expression is Controlled by an Estrogen Receptor (ER)-NFκB-miR-181 Regulatory Loop and is Essential for Formation of ER+ Mammospheres

J. Frasor, Irida Kastrati, E. Canestrari, 2014, Oncogene.

Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer

V. Catalano, I. Floriani, B. Vincenzi, 2009, The Pharmacogenomics Journal.

Association of BRAF mutations and EGFR Intron-1 L/L genotype with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients.

B. Vincenzi, D. Santini, M. Magnani, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy

V. Catalano, G. Fiorentini, B. Vincenzi, 2014, BMC Cancer.

Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer.

F. Cappuzzo, V. Catalano, G. Fiorentini, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

397 AUTOLOGOUS MUSCLE DERIVED CELLS TREATMENT OF FECAL INCONTINENCE: AN ANALYSIS OF EFFICACY IN WOMEN WITH OBSTETRIC INJURY

E. Canestrari, R. Jankowski, M. Raval, 2022, Continence.

Genetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy

V. Catalano, G. Fiorentini, B. Vincenzi, 2014, BMC Cancer.

Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.

M. Magnani, F. Graziano, A. Ruzzo, 2010, Current cancer drug targets.

Characterization of a pathogen reduced human platelet lysate

E. Canestrari, S. Harris, S. Charlebois, 2018 .

Ribonucleases as Drug Targets.

Z. Paroo, E. Canestrari, 2018, Trends in pharmacological sciences.